Literature DB >> 11263771

Infection efficiency of type 5 adenoviral vectors in synovial tissue can be enhanced with a type 16 fiber.

P H Goossens1, M J Havenga, E Pieterman, A A Lemckert, F C Breedveld, A Bout, T W Huizinga.   

Abstract

OBJECTIVE: To obtain an adenoviral vector with increased infection efficiency in the synovial tissue compared with conventional vectors based on adenovirus serotype 5 (Ad5), without compromising the specificity of infection.
METHODS: Coxsackie adenovirus receptor (CAR) expression was assessed in cultured synoviocytes. Chimeric adenoviruses based on Ad5 but carrying the DNA encoding the fiber of adenovirus from subgroup B (Adll, 16, 35) or D (Ad24, 28, 33, 45, or 47) were constructed and produced on PER.C6 cells. The gene transfer efficiency of these chimera was tested on cultured synoviocytes and peripheral blood mononuclear cells (PBMC).
RESULTS: No surface expression of CAR protein was observed on synoviocytes. CAR messenger RNA expression of synoviocytes was found to be low. Of all fiber chimeric vectors tested, vectors carrying the fiber of Ad16 (Ad5.fib16) were most potent, yielding approximately150 times increased transgene expression in cultured synoviocytes compared with those of Ad5. Flow cytometry showed that the increase in transgene expression was caused by the transduction of higher percentages of synoviocytes and higher gene expression per synoviocyte. Experiments with 500 virus particles/cell of Ad5.GFP or Ad5.fib16.GFP resulted in an infection efficiency of 0.6% and 1% in PBMC and 43% and 76% in synoviocytes, respectively.
CONCLUSION: Synoviocytes hardly express CAR, which hampers Ad5-mediated gene transfer. Ad5.fib16 is superior to Ad5 vectors for transducing synoviocytes, without compromising the specificity of infection. Our data suggest that Ad5.fib16-mediated gene transfer to synovial tissue improves the therapeutic window.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11263771     DOI: 10.1002/1529-0131(200103)44:3<570::AID-ANR105>3.0.CO;2-Y

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  7 in total

1.  Exploiting the natural diversity in adenovirus tropism for therapy and prevention of disease.

Authors:  M J E Havenga; A A C Lemckert; O J A E Ophorst; M van Meijer; W T V Germeraad; J Grimbergen; M A van Den Doel; R Vogels; J van Deutekom; A A M Janson; J D de Bruijn; F Uytdehaag; P H A Quax; T Logtenberg; M Mehtali; A Bout
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

2.  Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity.

Authors:  Ronald Vogels; David Zuijdgeest; Richard van Rijnsoever; Eric Hartkoorn; Irma Damen; Marie-Pierre de Béthune; Stefan Kostense; Germaine Penders; Niels Helmus; Wouter Koudstaal; Marco Cecchini; Antoinette Wetterwald; Mieke Sprangers; Angelique Lemckert; Olga Ophorst; Björn Koel; Michelle van Meerendonk; Paul Quax; Laura Panitti; Jos Grimbergen; Abraham Bout; Jaap Goudsmit; Menzo Havenga
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

Review 3.  Gene therapy works in animal models of rheumatoid arthritis...so what!

Authors:  Fons A J van de Loo; Jeroen Geurts; Wim B van den Berg
Journal:  Curr Rheumatol Rep       Date:  2006-10       Impact factor: 4.592

Review 4.  Transductional targeting of adenovirus vectors for gene therapy.

Authors:  J N Glasgow; M Everts; D T Curiel
Journal:  Cancer Gene Ther       Date:  2006-01-27       Impact factor: 5.987

5.  Potential of equine herpesvirus 1 as a vector for immunization.

Authors:  Sascha Trapp; Jens von Einem; Helga Hofmann; Josef Köstler; Jens Wild; Ralf Wagner; Martin Beer; Nikolaus Osterrieder
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

6.  PUMA gene delivery to synoviocytes reduces inflammation and degeneration of arthritic joints.

Authors:  Saw-See Hong; Hubert Marotte; Guillaume Courbon; Gary S Firestein; Pierre Boulanger; Pierre Miossec
Journal:  Nat Commun       Date:  2017-07-27       Impact factor: 14.919

Review 7.  Gene therapy for arthritis.

Authors:  Russell S Traister; Raphael Hirsch
Journal:  Mod Rheumatol       Date:  2008-01-05       Impact factor: 3.023

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.